Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630318 | 0.73 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAEPHX2TDP1ALDH1A1 | |
| Adamantane SCHEMBL2954042 | 0.72 | KMT2A (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1778693 | 0.72 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNAFDFT1GGPS1ABCG2 | |
| SCHEMBL9974906 | 0.72 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAEPHX2TDP1ALDH1A1 | |
| SCHEMBL5385637 | 0.70 | LMNA (0.48) | SMN1; SMN2LMNAFDFT1GGPS1ABCG2 | |
| SCHEMBL11228127 | 0.69 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAEPHX2TDP1ALDH1A1 | |
| SCHEMBL150989 | 0.69 | HSD11B1 (0.39) | — | |
| SCHEMBL6686034 | 0.69 | L3MBTL1 (0.45) | SMN1; SMN2LMNAEPHX2TDP1ALDH1A1 | |
| SCHEMBL4067246 | 0.68 | DPP4 (0.42) | SMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL6949868 | 0.67 | SIGMAR1 (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630921-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-25 | — | — | US | disclosed |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422284-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20160002229-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| US-9150512-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-10-06 | — | — | US | disclosed |
| US-20140179732-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-26 | — | — | US | disclosed |
| US-8563591-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-22 | — | — | US | disclosed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | disclosed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | disclosed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2003064372-A1 | 2-ADAMANTYLALKYLAMINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002229-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SMN1; SMN2 4409/4885LMNA 3306/4885FDFT1 34/4885 |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | CHRM1, CHRNA7, CHRM5 | SMN1; SMN2 3455/4885LMNA 1380/4885FDFT1 3277/4885 |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SMN1; SMN2 4409/4885LMNA 3306/4885FDFT1 34/4885 |
| US-20140179732-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SMN1; SMN2 4409/4885LMNA 3306/4885FDFT1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.